Kim JK, Chen CT, Keshinro A, Khan A, Firat C, Vanderbilt C, Segal N, Stadler Z, Shia J, Balachandran VP, Weiser MR. 2022. Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes. OncoImmunology 11:e2054757.

Weiser MR, Hsu M, Bauer PS, Chapman WC Jr., Gonzalez I,  Chatterjee D, Lingam D, Mutch MG, Keshinro A, Shia J, Vakiani E, Konishi T, Shimada Y, Stadler Z, Segal NH, Cercek A, Saltz L, Yaeger R, Varghese A,  Widmar M, Wei IH, Pappou EP, Smith JJ, Nash G, Paty P, Garcia-Aguilar J, Gonen M. 2021. Clinical calculator based on molecular and clinicopathologic characteristics predicts recurrence following resection of stage I-III colon cancer. J. Clin. Oncol. 39:911–919.

Weiser MR, Chou JF, Keshinro A, Chapman W, Bauer PS, Mutch MG, Parikh PJ, Cercek A, Saltz LB, Gollub MJ, Romesser PB, Crane CH, Shia J, Markowitz AJ, Garcia-Aguilar J, Gonen M, Colorectal Cancer Disease Management Team of Memorial Sloan Kettering Cancer Center. 2021. Development and assessment of a clinical calculator for estimating the likelihood of recurrence and survival among patients with locally advanced rectal cancer treated with chemotherapy, radiotherapy, and surgery. JAMA Netw. Open 4:e2133457.

Keshinro A, Vanderbilt C, Kim JK, Firat C, Chen CT, Yaeger R, Ganesh K, Segal NH, Gonen M, Shia J, Stadler Z, Weiser MR. 2021. Tumor-infiltrating lymphocytes, tumor mutational burden, and genetic alterations in microsatellite unstable, microsatellite stable, or mutant POLE/POLD1 colon cancer. JCO Precis. Oncol. 5:817–826.

Jimenez-Rodriguez RM, Patil S, Keshinro A, Shia J, Vakiani E, Stadler Z, Segal NH, Yaeger R, Konishi T, Shimada Y, Widmar M, Wei I, Pappou E, Smith JJ, Nash G, Paty P, Garcia-Aguilar J, Weiser MR. 2020. Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. OncoImmunology 9:1841948.

Roxburgh CSD, Strombom P, Lynn P, Cercek A, Gonen M, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Shia J, Vakiani E, Yaeger R, Stadler ZK, Segal NH, Reidy D, Varghese A, Wu AJ, Crane CH, Gollub MJ, Saltz LB, Garcia-Aguilar J, Weiser MR. 2019. Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes. Colorectal Dis. 21:1140–1150.

Konishi T, Shimada Y, Hsu M, Wei IH, Pappou E, Smith JJ, Nash GM, Guillem JG, Paty PB, Garcia-Aguilar J, Cercek A, Yaeger R, Stadler ZK, Segal NH, Varghese A, Saltz LB, Shia J, Vakiani E, Gönen M, Weiser MR. 2019. Contemporary validation of a nomogram predicting colon cancer recurrence, revealing all-stage improved outcomes. JNCI Cancer Spectr. 3:pkz015.

Roxburgh CS, Shia J, Vakiani E, Daniel T, Weiser MR. 2018. Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer.  OncoImmunology 7:e1435227.

Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, Yaeger R, Saltz L, Smith JJ, Nash GM, Guillem JG, Paty PB, Garcia-Aguilar J, Gonen M, Weiser MR. 2018. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 4:309–315.

Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Seier K, Gonen M, Segal NH, Reidy DL, Varghese A,  Shia J, Vakiani E, Wu AJ, Crane CH, Gollub MJ, Garcia-Aguilar J, Saltz LB, Weiser MR. 2018. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 4:e180071.

Vakiani E, Shah RH, Berger MF, Makohon-Moore AP, Reiter JG, Ostrovnaya I, Attiyeh MA, Cercek A, Shia J, Iacobuzio-Donahue CA, Solit DB, Weiser MR. 2017. Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget 8:42487–42494.

Trakarnsanga A, Gonen M, Shia J, Nash G, Temple L, Guillem, J, Paty P, Goodman K, Wu A, Gollub M, Segal N, Saltz L, Garcia-Aguilar J, Weiser MR. 2014. Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. J. Natl. Cancer Inst. 106:dju248.

Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen A, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR. 2011. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. Clin. Cancer Res. 17:122–133.

Weiser MR, Gonen M, Chou J, Kattan MW, Schrag D. 2011. Predicting survival following curative colectomy for cancer: individualizing colon cancer staging. J. Clin. Oncol. 29:4796–4802.

Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. 2011. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin. Cancer Res. 17:472–482.

Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD. 2008. Individualized prediction of colon cancer recurrence using a nomogram. J. Clin. Oncol. 26:380–385.

Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, Weiser MR. 2008. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol. Cancer Ther. 7:3499–3508.

Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR.  2007. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett. 248:219–228.

Francone TD, Landmann RG, Chen CT, Sun MY, Kuntz EJ, Zeng Z, Dematteo RP, Paty PB, Weiser MR. 2007. Novel xenograft model expressing human HGF demonstrates ligand-dependent growth of c-Met expressing tumors. Mol. Cancer Ther. 6:1460­–1466.